VENCLYXTO® offers patients with CLL a chance to
BREAK FREE with longer progression-free survival1*†
NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab
NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab
In 2L+ CLL:
VENCLYXTO + rituximab
*Reduced risk of progression or death vs O+Clb (HR=0.35; 95% CI: 0.23–0.53 [P<0.0001]). Median follow‑up of 28 months. Median PFS not reached in either arm.
†Reduced risk of progression or death vs BR (HR=0.17; 95% CI: 0.11–0.25 [P<0.0001]). Median follow‑up of 23.8 months. Median PFS not reached with VEN+R vs 17 months (15.5–21.6) with BR.
Instructions for taking VENCLYXTO1
When administering VENCLYXTO, advise patients as follows:
Be adequately hydrated every day when taking VENCLYXTO to reduce the risk of TLS.
Adequate hydration is particularly important 2 days before and on the day of the first dose, and every time the dose is increased. The recommended volume is 1.5–2 L of water (6–8 glasses) each day.
Take VENCLYXTO orally once daily with a meal and water at approximately the same time each day.
Swallow the VENCLYXTO tablets whole.
The tablets should not be chewed, crushed, or broken before swallowing.
In case of a missed dose, advise patients as follows:
If a patient misses a dose within 8 hours from the time it is usually taken:
The patient should take the missed dose right away and take the next dose as usual.
If a patient misses a dose by more than 8 hours:
The patient should not take the missed dose and should take the next dose at the usual time.
If a patient vomits following dosing:
No additional dose should be taken that day. The next prescribed dose should be taken at the usual time the next day.
CLL=chronic lymphocytic leukemia; 1L=first line; 2L+=second line + later lines of therapy; O+Clb=obinutuzumab + chlorambucil; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO + rituximab; TLS=tumor lysis syndrome.
[Placeholder for safety balance required by local regulations]
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
I want to find out
more
about VENCLYXTO
I want to receive more information about VENCLYXTO
Reference: 1. VENCLYXTO Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG. <Current SmPC.>
GR-VNCCLL-200048 -JAN2021